Related Experiment Video

Updated: Aug 20, 2026

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources
10:24

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Published on: January 27, 2026

How should we move the field of chemopreventive agent development forward in a productive manner?

Frank Louis Meyskens1, Eva Szabo

  • 1Department of Internal Medicine (Hematology/Oncology) and Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA 92868, USA. flmeyske@msx.ndc.mc.uci.edu

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|January 15, 2005
PubMed

Insights

Preventing precancerous lesions may control cancer, but human trials face challenges. This study offers guidelines for developing chemoprevention strategies more effectively.

Area of Science:

  • Oncology
  • Preventive Medicine
  • Clinical Trials

Background:

  • Epidemiologic and preclinical data suggest cancer prevention via precancer reversal is promising.
  • Human "proof of principle" for chemoprevention exists, but randomized trial results are often inconclusive.
  • Anticipated toxicity in healthy populations has been a significant concern in chemoprevention trials.

Purpose of the Study:

  • To examine the challenges in testing human chemoprevention agents.
  • To propose a structured process and guidelines for the logical development of clinical chemoprevention.
  • To advance the field of cancer chemoprevention research.

Main Methods:

  • Review of existing epidemiologic and preclinical evidence.
  • Analysis of outcomes from previous randomized chemoprevention trials.
  • Development of a proposed framework and guidelines for future research.

Main Results:

  • Human chemoprevention trials have yielded non-confirmatory results.
  • Toxicity issues in normal populations have exceeded expectations.
  • A need for improved strategies in designing and conducting chemoprevention studies is evident.

Conclusions:

  • Chemoprevention holds potential for cancer control but requires rigorous development.
  • Addressing toxicity and improving trial design are crucial for success.
  • The proposed guidelines aim to enhance the logical progression of this clinical field.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...